PMEL and melanoma: 27% of melanoma patients had objective partial responses with the treatment of CP-870893, which, however, was not reproducible.684,685 Combined regimens containing CP- 870893 with tremelimumab or the immune stimulant, oncovir poly IC:LC, along with a melanoma vaccine, NY-ESO-1/gp100, are under evaluation in a phase I trial in patients with melanoma.